Mushi Samuel Raymond, Kalezi Zawadi Edward, Simbila Alphonce Nsabi
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Department of Pediatric Cardiology, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania.
Pan Afr Med J. 2024 Aug 16;48:181. doi: 10.11604/pamj.2024.48.181.41906. eCollection 2024.
diuretic therapy is among the cornerstones of the management of heart failure in children with acquired or congenital heart diseases (CHD). Electrolyte derangements have been reported by various studies to be among the most common side effects following diuretic therapy. Despite that, there is limited documentation on the magnitude of this problem in our setting. This study, therefore, aimed to identify clinical characteristics and determine the magnitude of electrolyte abnormalities among children with heart failure who were on diuretic therapy at Jakaya Kikwete Cardiac Institute, Tanzania.
this hospital-based cross-sectional study was conducted among children with heart failure admitted at Jakaya Kikwete Cardiac Institute (JKCI), Dar es Salaam, Tanzania. A pretested structured questionnaire was used to collect data on socio-demographics, clinical characteristics, and levels of serum electrolytes.
a total of 385 children whose ages ranged from 1 month to 18 years were enrolled in this study. Most of them (271 (70%)) were below 5 years and their median age was 2.1 (IQR=0.8-6) years. Ventricular septal defect (VSD) was the most common acyanotic CHD, observed in 122 children out of 385 (31.6%). Nearly half (186 (48%)) of the children were in class IV of the Ross Heart Failure Classification. Slightly more than half of the study participants (202 (53%)) and 182 (47%) of the children had hyponatremia and hypocalcemia respectively. Only 8% (32/385) had hypokalemia. There was no observed association between hyponatremia and furosemide dosage (P=0.33) in children in this study.
a significant number of children with heart failure on diuretic therapy had hyponatremia and hypocalcemia hence, routine electrolytes monitoring is recommended.
利尿剂治疗是患有后天性或先天性心脏病(CHD)的儿童心力衰竭管理的基石之一。多项研究报告称,电解质紊乱是利尿剂治疗后最常见的副作用之一。尽管如此,在我们的环境中,关于这个问题严重程度的记录有限。因此,本研究旨在确定坦桑尼亚贾卡亚·基奎特心脏病研究所接受利尿剂治疗的心力衰竭儿童的临床特征,并确定电解质异常的严重程度。
这项基于医院的横断面研究是在坦桑尼亚达累斯萨拉姆的贾卡亚·基奎特心脏病研究所(JKCI)收治的心力衰竭儿童中进行的。使用预先测试的结构化问卷收集社会人口统计学、临床特征和血清电解质水平的数据。
本研究共纳入385名年龄在1个月至18岁之间的儿童。其中大多数(271名(70%))年龄在5岁以下,中位年龄为2.1岁(四分位间距=0.8-6岁)。室间隔缺损(VSD)是最常见的非青紫型CHD,在385名儿童中有122名(31.6%)观察到。近一半(186名(48%))儿童处于罗斯心力衰竭分类的IV级。略多于一半的研究参与者(202名(53%))和182名(47%)儿童分别患有低钠血症和低钙血症。只有8%(32/385)患有低钾血症。在本研究的儿童中,未观察到低钠血症与呋塞米剂量之间的关联(P=0.33)。
大量接受利尿剂治疗的心力衰竭儿童患有低钠血症和低钙血症,因此建议进行常规电解质监测。